Open AccessExpression, function and clinical application of stanniocalcin‐1 in cancer
Author(s) -
Zhao Fangyu,
Yang Gang,
Feng Mengyu,
Cao Zhe,
Liu Yueze,
Qiu Jiangdong,
You Lei,
Zheng Lianfang,
Zhang Taiping,
Zhao Yupei
Publication year - 2020
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.15348
Subject(s) - paracrine signalling , autocrine signalling , carcinogenesis , cancer , biology , endocrine system , function (biology) , bioinformatics , cancer research , biomarker , hormone , endocrinology , microbiology and biotechnology , receptor , genetics
The glycoprotein stanniocalcin‐1 functions as a regulatory endocrine hormone that maintains the balance of calcium and phosphorus in bony fish and as a paracrine/autocrine factor involved in many physiological/pathological processes in humans, including carcinogenesis. In this review, we provide an overview of (a) the possible mechanisms through which STC1 affects the malignant properties of cancer, (b) transcriptional and post‐transcriptional regulation pathways of STC1 and (c) the potential clinical relevance of STC1 as a cancer biomarker and even a therapeutic target in the future. Exploring the role of STC1 in cancer development may provide a better understanding of the tumorigenesis process in humans and may facilitate finding an effective therapeutic method against cancer.